About Kronos Bio
Kronos Bio is a Healthcare company based in San Mateo (United States) founded in 2017, and was acquired by Concentra Biosciences in May 2025. Small molecule therapeutics for cancer treatment are developed. Kronos Bio has raised $271.01 million across 3 funding rounds from investors including Fidelity Investments, BlackRock and Citadel. The company has 97 employees. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is KRONOS BIO, INC. Its competitors include Sana Biotechnology, Janux Therapeutics and GigaGen; 3 of its 3 listed competitors have raised funding.
Company details
Kronos Bio was founded in 2017 and is based in San Mateo, United States. Operations focus on the biotechnology sector, where small molecule-based therapeutics are created to address cancer. These molecules are designed to bind directly to target proteins, interfere with their activity, disrupt protein-protein complexes, or influence adjacent proteins for indirect modulation. The companys domain is kronosbio.com.
- Headquarters San Mateo, United States
- Employees 97
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website kronosbio.com
- Social LinkedIn X
- Acquired by Concentra Biosciences (May 2025)
- Legal Name Kronos Bio, Inc.
- Annual Revenue$9.85 M (USD)57as on Dec 31, 2024
- Net Profit-$86.08 M (USD)24as on Dec 31, 2024
- EBITDA-$92.89 M (USD)24as on Dec 31, 2024
- Total Equity Funding$271.01M (USD)
in 3 rounds
- Latest Funding Round$148M (USD), Series B
Aug 2020
- InvestorsFidelity Investments
& 19 more
- Employee Count97
- Acquired byConcentra Biosciences
(May 2025)
Funding Insights of Kronos Bio
Kronos Bio has successfully raised a total of $271.01M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $148 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $271.01M
- Total Rounds 3
- Last Round Series B — $148M
- First Round $18.01M
(May 2018)
- Investors Count 19
All 3 funding rounds of Kronos Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $148M | Series B | – | Perceptive Advisors | |
| Jul 2019 | $105M | Series A | – | Vida Ventures, Omega Funds | |
| May 2018 | $18.01M | Seed | – | Omega Funds, Bellco Capital |
20 investors in total: 17 institutional and 3 angel.
Investors in Kronos Bio
Kronos Bio has secured backing from 20 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Fidelity Investments, BlackRock and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Venture capital is provided to healthcare startups by Commodore Capital. | commodorecapital.com | New York, United States | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Long-term private equity investments in transformational opportunities are pursued. | invus.com | New York, United States | ||
Biomedical innovations are transformed into therapies by Vida Ventures. | vidaventures.com | Boston, United States | ||
Venture capital firm | omegafunds.com | Boston, United States | ||
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
Two River is engaged in building life science companies. | tworiver.com | New York, United States |
Investor details for Kronos Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Kronos Bio
23 people are tracked at Kronos Bio (6 in leadership, 12 in board & advisors, 5 in team); the tracked headcount is 97.
| Name | Role | Group |
|---|---|---|
Jorge DiMartino | Chief Medical Officer & EVP, Clinical Development | Leadership |
Norbert Bischofberger | President & CEO | Leadership |
Kathryn Adamiak | VP, Finance | Leadership |
Rocio Martin Hoyos | VP, Commercial Strategy | Leadership |
Kathleen Guindon | Senior Director, Medical Science Liaison | Leadership |
Cindy Dodd | Senior Director, Fp&a | Leadership |
Otello Stampacchia | Director | Board & advisors |
David Tanen | Director | Board & advisors |
Angela Koehler | Scientific Advisor | Board & advisors |
Joshua Kazam | Director | Board & advisors |
Myles Brown | Scientific Advisor | Board & advisors |
Taiyin Yang | Director | Board & advisors |
Elena Ridloff | Director | Board & advisors |
Robert Eisenman | Scientific Advisor | Board & advisors |
Arie Belldegrun | Director | Board & advisors |
Owen Witte | Scientific Advisor | Board & advisors |
Roger Dansey | Director | Board & advisors |
Roshawn Blunt | Director | Board & advisors |
Jean Allen | Sr. Manager, Payroll & Equity Administration | Team |
Elizabeth Olek | SVP, Clinical Development | Team |
3 more people are available in the full profile.
Complete people profiles for Kronos Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Kronos Bio
5 dated milestones of Kronos Bio across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Kronos Bio is founded.
- Funding First funding round of $18.0M.
- Funding Latest funding round, Series B, of $148.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Concentra Biosciences.
Competitors of Kronos Bio
Kronos Bio has 3 listed competitors in our database, 3 of them funded. They include Sana Biotechnology, Janux Therapeutics and GigaGen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| januxrx.com | 2017 | San Diego, United States | $181M | 59 | Immunotherapeutics for cancer treatment are developed to target solid tumors. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. |
Detailed competitors of Kronos Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Kronos Bio
The website of Kronos Bio (kronosbio.com) receives about 3.2K visits a month and ranks #6,463,734 among all websites worldwide, #6,592 in Biotechnology and Pharmaceuticals.
- Monthly visits3.2K
▲ 40.6% vs previous month
- Global rank#6,463,734
among all websites
- Category rank#6,592
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit2.3
- Average visit1 min 05 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Kronos Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
bioworld.com | bioworld.com | 100% | #311,180 | – |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Kronos Bio (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Kronos Bio
Complete news archive for Kronos Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kronos Bio
Kronos Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Kronos Bio is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Kronos Bio is a funded company, having raised a total of $271.01M across 3 funding rounds to date. The company's 1st funding round was a Seed of $18.01M, raised on May 2018.
Kronos Bio has 97 employees.
Annual revenue of Kronos Bio is $9.85M as on Dec 31, 2024.
Kronos Bio was founded in 2017 and is based in San Mateo, United States. Operations focus on the biotechnology sector, where small molecule-based therapeutics are created to address cancer. These molecules are designed to bind directly to target proteins, interfere with their activity, disrupt protein-protein complexes, or influence adjacent proteins for indirect modulation. The companys domain is kronosbio.com.
Kronos Bio's top competitors include Janux Therapeutics, Sana Biotechnology and GigaGen.
Kronos Bio has 20 investors. Key investors include Fidelity Investments, BlackRock, Citadel, Perceptive Advisors, and Commodore Capital.
Kronos Bio operates through Kronos Bio, Inc..
Yes. Kronos Bio was acquired by Concentra Biosciences in May 2025.